The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Abstract
A locus segregating with familial Alzheimer's disease (AD) has been mapped to chromosome 21, close to the amyloid precursor protein (APP) gene. Recombinants between the APP gene and the AD locus have been reported which seemed to exclude it as the site of the mutation causing familial AD. But recent genetic analysis of a large number of AD families has demonstrated that the disease is heterogeneous. Families with late-onset AD do not show linkage to chromosome 21 markers. Some families with early-onset AD show linkage to chromosome 21 markers, but some do not. This has led to the suggestion that there is non-allelic genetic heterogeneity even within early onset familial AD. To avoid the problems that heterogeneity poses for genetic analysis, we have examined the cosegregation of AD and markers along the long arm of chromosome 21 in a single family with AD confirmed by autopsy. Here we demonstrate that in this kindred, which shows linkage to chromosome 21 markers, there is a point mutation in the APP gene. This mutation causes an amino-acid substitution (Val----Ile) close to the carboxy terminus of the beta-amyloid peptide. Screening other cases of familial AD revealed a second unrelated family in which this variant occurs. This suggests that some cases of AD could be caused by mutations in the APP gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FAD mutations in APP that cluster near the 𝛃 - and 𝛄 -secretase cleavage sites either elevate the production of total A 𝛃 , as is the case with the K670N/ M671L substitution [Swedish mutation (Mullan et al., 1992a)], or increase the generation of A 𝛃 42 specifically, as occurs with the I716V [Florida mutation (Eckman et al., 1997)] and V717I [London mutation (Goate et al., 1991)] substitutions.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Goate et al., 1991
In the citing paper
“The 5XFAD mouse, along with the APPSLPS1KI, is one of a few known mouse models that exhibits significant neuron loss in addition to displaying other AD hallmarks such as amyloid plaques [10,11,16].”
From Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation (2013) · cites this paper as [10]
In the citing paper
“Frank neuron loss has been observed in two aggressive amyloid plaque transgenic mouse models that also exhibit accumulation of intraneuronal Aβ42 prior to plaque formation: the 5XFAD and APPSLPS1K1 lines [10,11].”
From Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation (2013) · cites this paper as [10]
In the citing paper
“Early onset Alzheimer's disease can be caused by mutations in the APP (Chartier-Harlin et al., 1991;Goate et al., 1991;Murrell et al., 1991;Mullan et al., 1992), presenilin 1 (PS1) (Sherrington et al., 1995), and presenilin 2 (PS2) (Levy-Lahad et al., 1995) genes.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Goate et al., 1991
In the citing paper
“The amyloid cascade hypothesis of Alzheimer disease (AD), which proposes that deposition of the amyloid-β (Aβ) peptide in the brain is a central event in disease pathology (Figure 1), is strongly supported by neuropathological and human genetic evidence”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [2]
In the citing paper
“Mutations in APP, presenilin 1 (PSEN1) and PSEN2 genes that increase Aβ production, elevate Aβ42/Aβ40 ratio and promote plaque formation cause autosomal dominant early-onset familial AD (FAD)”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [38]
In the citing paper
“Less than 1% of all AD cases are early-onset with symptoms developed at an age of 50 s and earlier, and caused by gene mutations in APP, PSEN1 or PSEN2.7,38,39”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [38]
In the citing paper
“This hypothesis gained favor in the 1990s after several gene mutations directly responsible for aberrant Aβ accumulation (APP, PSEN1, PSEN2) were found to underlie rare familial forms of early-onset AD [20–22].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [21]
Citations
Cites
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Garnier, J., Osguthorpe, D. J., & Robson, B. (1978) · Journal of Molecular Biology · doi:10.1016/0022-2836(78)90297-8 · Cited by 4,523
Strategies for multilocus linkage analysis in humans.
Lathrop, M. G., Lalouel, J.-M., Julier, C., & Ott, J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3443 · Cited by 2,560
Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91209-9 · Cited by 1,693
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I. M., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,399
Goldgaber, D., Lerman, M. I., McBride, O. W., Saffiotti, U., & Gajdusek, D. C. (1987) · Science · doi:10.1126/science.3810169 · Cited by 1,359
The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
George‐Hyslop, P. S., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L. E., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D. A., Drachman, D. A., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,160
Hydrophobic cluster analysis: An efficient new way to compare and analyse amino acid sequences
Gaboriaud, C., Bissery, V., Benchetrit, T., & Mornon, J. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80439-8 · Cited by 618
Cited by
Sorted by citations
Items 1,001–1,066 of 1,066
Felsenstein, K. M., Hunihan, L. W., & Roberts, S. B. (1994) · Nature Genetics · doi:10.1038/ng0394-251 · Cited by 90
Bundy, J. L., Vied, C., Badger, C., & Nowakowski, R. S. (2019) · Journal of Comparative Neurology · doi:10.1002/cne.24551 · Cited by 90
Reelin-mediated signaling in neuropsychiatric and neurodegenerative diseases
Knuesel, I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.002 · Cited by 89
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
Role of common and rare APP DNA sequence variants in Alzheimer disease
Hooli, B. V., Mohapatra, G., Mattheisen, M., Parrado, A. R., Roehr, J. T., Shen, Y., Gusella, J. F., Moir, R., Saunders, A. J., Lange, C., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182515972 · Cited by 87
Myelin changes at the early stage of 5XFAD mice
Gu, L., Wu, D., Tang, X., Qi, X., Li, X., Bai, F., Chen, X., Ren, Q., & Zhang, Z. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.013 · Cited by 87
Roses, A. D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s340 · Cited by 86
Self-citationShifting paradigms: The central role of microglia in Alzheimer’s disease
Schwabe, T., Srinivasan, K., & Rhinn, H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104962 · Cited by 84
The Relationship between Amyloid and Tau
Hardy, J. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:2:203 · Cited by 80
Self-citationThe bipolar disorder phenome database: a resource for genetic studies
Potash, J. B., Toolan, J., Steele, J., Miller, E. B., Pearl, J., Zandi, P. P., Schulze, T. G., Kassem, L., Simpson, S. G., Lopez, V., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06122045 · Cited by 80
APOE and other loci affect age‐at‐onset in Alzheimer's disease families with PS2 mutation
Wijsman, E. M., Daw, E. W., Yu, X., Steinbart, E. J., Nochlin, D., Bird, T. D., & Schellenberg, G. D. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30087 · Cited by 79
Hashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107807 · Cited by 78
Identification of conserved proteomic networks in neurodegenerative dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Lah, J. J., Johnson, E. E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2019) · doi:10.1101/825802 · Cited by 78
Brickell, K. L., Steinbart, E. J., Rumbaugh, M., Payami, H., Schellenberg, G. D., Van Deerlin, V., Yuan, W., & Bird, T. D. (2006) · Archives of Neurology · doi:10.1001/archneur.63.9.1307 · Cited by 77
Locke, P. A., Conneally, P. M., Tanzi, R. E., Gusella, J. F., & Haines, J. L. (1995) · Genetic Epidemiology · doi:10.1002/gepi.1370120108 · Cited by 75
Choi, H. Y., Liu, Y., Tennert, C., Sugiura, Y., Karakatsani, A., Kröger, S., Johnson, E. B., Hammer, R. E., Lin, W., & Herz, J. (2013) · eLife · doi:10.7554/elife.00220 · Cited by 71
Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features
Giaccone, G., Morbin, M., Moda, F., Botta, M., Mazzoleni, G., Uggetti, A., Catania, M., Moro, M. L., Redaelli, V., Spagnoli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0747-1 · Cited by 73
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Relation of genomic variants for Alzheimer disease dementia to common neuropathologies
Farfel, J. M., Yu, L., Buchman, A. S., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002909 · Cited by 64
Translational approaches to understanding resilience to Alzheimer’s disease
Neuner, S. M., Telpoukhovskaia, M., Menon, V., O’Connell, K. M. S., Hohman, T. J., & Kaczorowski, C. C. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.02.005 · Cited by 68
“These proteinopathies are thought to be drivers of the neuronal dysfunction and cognitive impairment that characterize the disease [3], in part due to the identification of inherited mutations in amyloid precursor protein (APP) that cause familial forms of autosomal dominant AD [4].”
BackgroundWelsh‐Bohmer, K. A., Gearing, M., Saunders, A. M., Roses, A. D., & Mirra, S. (1997) · Annals of Neurology · doi:10.1002/ana.410420308 · Cited by 67
Self-citationHippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Del Amo, L., Cano, A., Ettcheto, M., Souto, E. B., Espina, M., Camins, A., García, M. L., & Sánchez-López, E. (2021) · Applied Sciences · doi:10.3390/app11094305 · Cited by 67
Jordà‐Siquier, T., Petrel, M., Kouskoff, V., Smailovic, U., Cordelières, F., Frykman, S., Müller, U., Mulle, C., & Barthet, G. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12546 · Cited by 63
Blood cell-produced amyloid-β induces cerebral Alzheimer-type pathologies and behavioral deficits
Sun, H.-L., Chen, S.-H., Yu, Z.-Y., Cheng, Y., Tian, D.-Y., Fan, D.-Y., He, C.-Y., Wang, J., Sun, P.-Y., Chen, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0842-1 · Cited by 56
Central and peripheral circadian clocks and their role in Alzheimer's disease
Chauhan, R., Chen, K.-F., Kent, B. A., & Crowther, D. C. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030627 · Cited by 58
“Genetic linkage studies in familial AD (Goate et al., 1991; Rogaev et al., 1995; Sherrington et al., 1995) and wholegenome studies of the more common, sporadic form of AD (Jonsson et al.”
BackgroundTurning the tide on Alzheimer’s disease: modulation of γ-secretase
Luo, J. E., & Li, Y.-M. (2022) · Cell & Bioscience · doi:10.1186/s13578-021-00738-7 · Cited by 59
Campos-Peña, V., Toral-Rios, D., Becerril-Pérez, F., Sánchez-Torres, C., Delgado-Namorado, Y., Torres-Ossorio, E., Franco-Bocanegra, D., & Carvajal, K. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6768 · Cited by 58
Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0152082 · Cited by 56
Ocular manifestations of Alzheimer's disease in animal models
Parnell, M., Guo, L., Abdi, M., & Cordeiro, M. F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/786494 · Cited by 56
Expression of BC1 Impairs Spatial Learning and Memory in Alzheimer’s Disease Via APP Translation
Zhang, T., Pang, P., Fang, Z., Guo, Y., Li, H., Li, X., Tian, T., Yang, X., Chen, W., Shu, S., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0820-z · Cited by 52
Sultana, R., Newman, S. F., Abdul, H. M., Cai, J., Pierce, W. M., Klein, J. B., Merchant, M., & Butterfield, D. A. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20876 · Cited by 53
Microtubule transport defects in neurological and ciliary disease
Gerdes, J. M., & Katsanis, N. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5007-5 · Cited by 51
Carlson, G. A., & Prusiner, S. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094861 · Cited by 51
Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Belin, A. C., Björk, B. F., Westerlund, M., Galter, D., Sydow, O., Lind, C., Pernold, K., Rosvall, L., Håkansson, A., Winblad, B., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.05.010 · Cited by 48
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Insights on the Use of Transgenic Mice Models in Alzheimer’s Disease Research
Pádua, M. S., Guil-Guerrero, J. L., Prates, J. A. M., & Lopes, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052805 · Cited by 46
Hamblet, N. S., & Castora, F. J. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00158-9 · Cited by 44
Mechanisms of memory loss in Aβ and tau mouse models
Ashe, K. H. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330591 · Cited by 42
Alzheimer’s disease: rare variants with large effect sizes
Del-Aguila, J. L., Koboldt, D. C., Black, K., Chasse, R., Norton, J., Wilson, R. K., & Cruchaga, C. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.07.008 · Cited by 41
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Age as Risk Factor for Sporadic Dementia of the Alzheimer Type?
HOYER, S. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb56833.x · Cited by 38
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
Evidence for three loci modifying age‐at‐onset of Alzheimer's disease in early‐onset PSEN2 families
Marchani, E. E., Bird, T. D., Steinbart, E. J., Rosenthal, E., Yu, C., Schellenberg, G. D., & Wijsman, E. M. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31072 · Cited by 29
Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
Liu, L., & Caselli, R. J. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.006 · Cited by 29
Tran, K. M., Kwang, N. E., Butler, C. A., Gomez-Arboledas, A., Kawauchi, S., Mar, C., Chao, D., Barahona, R. A., Da Cunha, C., Tsourmas, K. I., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00793-x · Cited by 28
Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease
Li, X., Tsolis, K. C., Koper, M. J., Ronisz, A., Ospitalieri, S., von Arnim, C. A. F., Vandenberghe, R., Tousseyn, T., Scheuerle, A., Economou, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12345 · Cited by 27
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
A Mutation in DAOA Modifies the Age of Onset in PSEN1 E280A Alzheimer’s Disease
Vélez, J. I., Rivera, D., Mastronardi, C. A., Patel, H. R., Tobón, C., Villegas, A., Cai, Y., Easteal, S., Lopera, F., & Arcos-Burgos, M. (2016) · Neural Plasticity · doi:10.1155/2016/9760314 · Cited by 25
Foidl, B. M., Do-Dinh, P., Hutter-Schmid, B., Bliem, H. R., & Humpel, C. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.09.014 · Cited by 24
Studies on the first described Alzheimer's disease amyloid β mutant, the Dutch variant
Levy, E., Prelli, F., & Frangione, B. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s337 · Cited by 24
Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease
D’Introno, A., Solfrizzi, V., Colacicco, A. M., Capurso, C., Amodio, M., Todarello, O., Capurso, A., Kehoe, P. G., & Panza, F. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.020 · Cited by 23
Allelic association between the D10S1423 marker and Alzheimer's disease in a German population
Majores, M., Bagli, M., Papassotiropoulos, A., Schwab, S. G., Jessen, F., Rao, M. L., Maier, W., & Heun, R. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01283-0 · Cited by 23
A microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
Mutations modifying sporadic Alzheimer’s disease age of onset
Vélez, J. I., Lopera, F., Patel, H. R., Johar, A. S., Cai, Y., Rivera, D., Tobón, C., Villegas, A., Sepulveda‐Falla, D., Lehmann, S. G., et al. (2016) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32493 · Cited by 19
Niwa, A., Matsuo, K., Shindo, A., Yata, K., Shiraishi, T., & Tomimoto, H. (2013) · Neuropathology · doi:10.1111/j.1440-1789.2012.01340.x · Cited by 16
Beta-amyloid oligomers: recent developments
Borutaite, V., Morkuniene, R., & Valincius, G. (2011) · bmc · doi:10.1515/bmc.2011.019 · Cited by 9
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Tian, Y., Hornburg, K., Austin, W., Cook, J. J., Qi, Y., White, L. E., Killmar, J. T., Kaczorowski, C. C., Ashbrook, D. G., Johnson, G. A., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-025-02199-4 · Cited by 1
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
Lendon, C. L., Martinez, A., Behrens, I. M., Kosik, K. S., Madrigal, L., Norton, J., Neuman, R., Myers, A., Busfield, F., Wragg, M., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)10:3
Self-citationCann, S. A. H., Netten, J. P. V., & Netten, C. V. (2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200003)47:3
Khan (2000) · doi:10.1002/1531-8249(200008)48:2
Jonnal (2000) · doi:10.1002/1096-8628(20001204)96:6
Metadata
- Authors
- Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, M., Owen, M., & Hardy, J.
- Affiliations
- St Mary's Hospital (GB)
- Yale University (US)
- University of Wales (GB)
- Duke Medical Center (US)
- Venue
- Nature
- Published
- 1991-02-21
- Volume
- 349
- Issue
- 6311
- Pages
- 704-706
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058723245
- Cited by
- 4,659
- References
- 30
- Citations by year
- 2026: 62 · 2025: 85 · 2024: 111 · 2023: 88 · 2022: 112 · 2021: 130 · 2020: 149 · 2019: 115 · 2018: 112 · 2017: 130 · 2016: 160 · 2015: 131 · 2014: 129 · 2013: 166 · 2012: 135
- FWCI
- 153.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute on Aging (AG05 128, P50AG005128)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- familial Alzheimer's disease, amyloid precursor protein gene, APP gene mutations, missense mutations, genetic heterogeneity, co-segregation, early-onset Alzheimer's disease, late-onset Alzheimer's disease, beta-amyloid peptide
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 21, Exons, Genetic Testing, Genotype, Humans, Genetic Linkage, Molecular Sequence Data, Mutation, Pedigree, Protein Precursors, Polymorphism, Restriction Fragment Length, Polymerase Chain Reaction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
